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INTRODUCTION

 oronary vasospasm secondary to chemotherapy
C
induced toxicity presents with angina, elevated cardiac
enzymes and electrocardiogram (ECG) changes.
Cardiotoxicity is a rare but known oncologic
emergency presenting after bolus or infusion
administration of 5-fluorouracil (5-FU).
In such cases, prompt discontinuation of the drug
and Cardiology consultation is required.
This case presents a patient who underwent 5-FU
induction therapy resulting in coronary vasospasm.

CASE PRESENTATION

A 71-year-old male with a history of atrial fibrillation,
hypertension, hyperlipidemia, COPD (On Home O2)
and colon cancer presented to the emergency
department with chest pain, diaphoresis and nausea.
The day prior to presentation the patient began a 48hour chemotherapy induction of 5-FU.
Presenting ECG demonstrated atrial fibrillation with
rapid ventricular response, right bundle branch block
and infero-lateral ST elevations (Figure 1). Troponin I
was elevated to a peak of 0.24. The 5-FU infusion
was stopped and the patient underwent coronary
angiography where no coronary atherosclerotic
disease was evident (Figure 2 and 3).
ECG post catheterization showed resolution of inferolateral ischemic changes (Figure 4)
The patient was continued on aspirin, clopidogrel
and atorvastatin and a long acting nitrate was added.
The patient had no further episodes of chest pain.
He had an extended hospital stay complicated by
acute on chronic respiratory failure. He eventually
recovered and was discharged for outpatient follow
up with hematology-oncology for an alternative
therapy for his colon cancer.
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ECG AND CARDIAC CATHETERIZATION
FINDINGS

Figure 1: Presenting ECG tracing demonstrating atrial fibrillation
with rapid ventricular response, right bundle branch block and
infero-lateral STEMI.

Figure 3: RAO caudal coronary angiogram image demonstrating
normal left circumflex and left anterior descending coronary
arteries.

Figure 2: AP cranial coronary angiogram image demonstrating a
normal, dominant right coronary artery.
Figure 4: ECG tracing post cardiac catheterization demonstrating
persistent atrial fibrillation, right bundle branch block and resolved
infero-lateral ischemia.
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DISCUSSION

5 -FU alone or in combination with other chemo
therapeutic agents has become the mainstay of
colorectal cancer treatments.
In rare cases (1.6%-8.5%), life-threatening coronary
vasospasm has resulted secondary to endothelial
1
dysfunction caused by 5-FU metabolites.
This cardiotoxicity tends to occur more commonly in
the first cycle of administration and 72% of affected
1,2
patients were aged greater than 55 years.
Symptoms and ECG findings at presentation are
highly suggestive of coronary occlusion and diagnosis
is supported by cardiac catheterization showing
patent coronaries.
This toxicity responds favorably to prompt discon
tinuation of 5-FU and the administration of antianginal
therapies such as calcium channel blockers.1
If diagnosed in a timely fashion, the toxicity is
commonly reversible and the prognosis, from a
cardiac perspective, is favorable.
Careful consideration is given to whether 5-FU can
be reinstituted or whether acceptable alternative
treatments can be safely used.
When further doses of 5-FU are required, clinicians
should proceed cautiously, consider using prophylactic
antianginal therapy and monitor patients closely with a
1
low threshold to discontinue therapy.

